|
Disease management and frontline treatment of locally advanced or metastatic urothelial (la/mUC) carcinoma: The U.S. physician PARADIGM study. |
|
|
Stock and Other Ownership Interests - Moderna Therapeutics; Nektar |
Honoraria - Bristol-Myers Squibb |
Consulting or Advisory Role - AVEO; EMD Serono; Gilead Sciences; Guardant Health; Loxo/Lilly; Merck; Pfizer |
Speakers' Bureau - Bristol-Myers Squibb; Janssen Oncology |
|
|
No Relationships to Disclose |
|
|
|
Travel, Accommodations, Expenses - EMD Serono |
|
|
Employment - Kantar Health |
Consulting or Advisory Role - EMD Serono (Inst) |
Research Funding - EMD Serono (Inst) |
|
|
|
Stock and Other Ownership Interests - Pfizer |
Research Funding - Pfizer (Inst) |
Travel, Accommodations, Expenses - Pfizer |
|
|
Employment - Kantar Health |
Consulting or Advisory Role - EMD Serono (Inst) |
Research Funding - EMD Serono (Inst) |
|
|
|
Stock and Other Ownership Interests - Pfizer |
|
|
|
|
|
|
Stock and Other Ownership Interests - EMD Serono |